Deepak Singh (CN Bio Innovations Ltd.)

Singh, Deepak (CN Innovations 202303– VP of Sales + Marketing at CN Bio before Horizon Discovery + PacBio + Affymetrix)

	Organisation	CN Bio Innovations Ltd.
	Group	CN Innovations (Group)
	Former/major organisation	Horizon Discovery Ltd.
	Group	PerkinElmer (Group)
	Product	organ-on-a-chip technology
	Product 2	PhysioMimix® Organs-on-Chips system

CN Bio Innovations Ltd.. (3/14/23). "Press Release: CN Bio Appoints Deepak Singh as Vice President of Sales and Marketing". Cambridge.

Key appointment as company seeks to continue global expansion of microphysiological systems and contract research service offerings

CN Bio, a leading Organ-on-a-chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), has today announced that is has appointed Deepak Singh as Vice President of Sales and Marketing. Deepak’s appointment supports the Company’s next phase of commercial development as it expands international operations, product research and development and sales in key global markets.

Bringing over 30 years of commercial experience within life sciences, Deepak’s appointment follows that of Dr Paul Brooks as CEO in December 20221, to drive CN Bio’s international scale-up operations for both the product and service sides of the business. This includes supporting the recent launch of the Company’s PhysioMimix® Single-organ Higher-Throughput (HT) System2, designed to overcome adoption barriers currently limiting the use of predictive human liver models within drug discovery workflows, enabling use within earlier stages where larger-scale comparative studies that investigate the efficacy, disposition or safety of lead candidate drugs are required.

Throughout his extensive career in the commercial life sciences sector, Deepak has provided leadership for high-performance sales and marketing teams to establish new technologies, from commercialisation through to global scale-up, as well as supporting expansion of existing products and services into the drug discovery, bioproduction, research and diagnostics markets. He joins CN Bio from PerkinElmer’s Horizon Discovery where he was Head of Global Commercial. Prior to this, Deepak was with Pacific Biosciences as Vice President of EMEA Operations. He also held senior-level sales and marketing positions at Affymetrix and the Genetic Analysis Unit of Applied Biosystems (formerly a PerkinElmer company). Deepak has a BSc in Biotechnology from the Polytechnic of Central London.

Deepak Singh, VP Sales and Marketing at CN Bio, commented: “Having had extensive experience within the life science industry, I am excited by the possibilities of OOC technology, and how fast the potential of this technology is being realised. As evidenced by the recent FDA Modernization Act 2.0 legislation in the US, this is a very promising time for the technology, and I am looking forward to joining the CN Bio team to bring their cutting-edge systems to more researchers across the globe, to enable decision-making within drug discovery workflows to be made with more confidence and earlier than ever before.”

Dr Paul Brooks, CEO at CN Bio, said: “Deepak’s business and leadership experience, alongside his life science background, is of huge value to CN Bio as we drive forward with the Company’s commercial excellence strategy and build our capabilities in 2023 and beyond. Following the successful launch of our PhysioMimix Single-organ HT System in February, Deepak joins us at an exciting time and will be pivotal for the international scale-up of the marketing and distribution of this new system and our existing portfolio of MPS products and services.”

1. Press release (19th December, 2022): CN Bio appoints Dr Paul Brooks as Chief Executive Officer https://cn-bio.com/cn-bio-appoints-dr-paul-brooks-as-chief-executive-officer/

2. Press release (27th February, 2023): CN Bio extends microphysiological system portfolio with PhysioMimix Single-Organ Higher Throughput System https://cn-bio.com/cn-bio-extends-microphysiological-system-portfolio-with-physiomimix-single-organ-higher-throughput-system/

ENDS

Notes to Editors

[photo] Deepak Singh, Vice President of Sales and Marketing at CN Bio
For a high-resolution image please contact Zyme Communications.

For further information please contact:

Zyme Communications
Lily Jeffery
Tel: +44(0)7891477378
Email: lily.jeffery@zymecommunications.com

CN Bio
Dr Sarah Payne, Product Marketing Manager
Email: sarah.payne@cn-bio.com

About CN Bio https://cn-bio.com/

CN Bio is a leading organ-on-a-chip (OOC) company that offers a portfolio of products and services to optimise the accuracy and efficiency of bringing new medicines to market; providing significant savings in cost and time to drug discovery and development pipelines. With more than a decade of research and development experience in multi-organ microphysiology, CN Bio aims to transform the way human-relevant pre-clinical data is generated through the development of the most complete model of the human “Body-on-a-Chip” in the laboratory.

The Company’s range of lab-benchtop PhysioMimix® microphysiological systems (MPS) enable researchers to model human biology in the lab through rapid and predictive 3D human tissue-based studies that harness microfluidic technology to provide nutrients and mimic blood flow. The technology bridges the gap between traditional cell culture and human studies, advancing towards the simulation of human biological conditions to support the accelerated and more efficient development of new therapeutics, whilst reducing the dependence on animal model usage.

CN Bio’s MPS support researchers that require reliable, data-rich, in vitro studies, to uncover novel mechanistic insights into a broad range of biological processes across healthy and diseased cell-types, in addition to identifying novel therapeutic targets and investigating drug efficacy, pharmacokinetics and potential toxicity.

The Company’s next-generation OOC assays span a range of organ types, including lung, liver and gut. Single organs can be linked together into multi-organ systems to simulate processes such as drug absorption and metabolism, or to understand interactions between organs, such as inflammation.

Harnessing these assays, its portfolio of MPS, 3D validated cells, compatible consumable plates and research services have been developed to address drug development bottlenecks across a range of therapeutic areas, including metabolic and infectious diseases, oncology, and inflammation.

CN Bio’s headquarters and laboratories are based in Cambridge, UK, with an international network of distributors.

Follow CN Bio on LinkedIn @CN Bio and Twitter @CN_Bio.